GSK, Ionis antiviral bepirovirsen earns early FDA approval for functional cure

The FDA granted early approval for GSK and Ionis’ chronic hepatitis B drug bepirovirsen, now branded Hibsago, as a functional-cure therapy candidate. The early timing sets up a potential blockbuster trajectory while the program moves through late-stage commercialization planning.